Martina S J McDermott
Overview
Explore the profile of Martina S J McDermott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McDermott M, Browne B, Conlon N, OBrien N, Slamon D, Henry M, et al.
Mol Cancer
. 2023 Nov;
22(1):175.
PMID: 37915024
No abstract available.
2.
OBrien N, McDermott M, Zhang J, Gong K, Lu M, Hoffstrom B, et al.
Mol Cancer Ther
. 2023 Oct;
22(12):1365-1375.
PMID: 37788341
Gastric and pancreatic cancers are malignancies of high unmet clinical need. Expression of CLDN18.2 in these cancers, coupled with it's absence from most normal tissues, provides a potential therapeutic window...
3.
Gaynor N, Blanco A, Madden S, Moran B, Fletcher J, Kaukonen D, et al.
Br J Cancer
. 2023 Jul;
129(6):1022-1031.
PMID: 37507543
Background: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy in combination with trastuzumab, lapatinib or both in patients with HER2+ breast cancer. We studied circulating immune cells looking...
4.
McDermott M, OBrien N, Hoffstrom B, Gong K, Lu M, Zhang J, et al.
Clin Cancer Res
. 2023 Mar;
29(11):2131-2143.
PMID: 36884217
Purpose: Claudin-6 (CLDN6) is expressed at elevated levels in multiple human cancers including ovarian and endometrial malignancies, with little or no detectable expression in normal adult tissue. This expression profile...
5.
Ding X, Sharko A, McDermott M, Schools G, Chumanevich A, Ji H, et al.
Proc Natl Acad Sci U S A
. 2022 Aug;
119(32):e2201073119.
PMID: 35914167
Breast cancers (BrCas) that overexpress oncogenic tyrosine kinase receptor HER2 are treated with HER2-targeting antibodies (such as trastuzumab) or small-molecule kinase inhibitors (such as lapatinib). However, most patients with metastatic...
6.
OBrien N, Huang H, McDermott M, Madrid A, Luo T, Ayala R, et al.
Mol Cancer Ther
. 2022 Apr;
21(5):751-761.
PMID: 35417017
Pharmacologically targeting the HER2 oncoprotein with therapeutics such as the mAb, trastuzumab, provides clinical benefit for patients with HER2-positive (HER2+) cancers. However, a significant number of patients eventually progress on...
7.
Sharko A, Lim C, McDermott M, Hennes C, Philavong K, Aiken T, et al.
Cells
. 2021 Jan;
10(1).
PMID: 33445730
Drug resistance is the main obstacle to achieving cures with both conventional and targeted anticancer drugs. The emergence of acquired drug resistance is initially mediated by non-genetic transcriptional changes, which...
8.
OBrien N, McDermott M, Conklin D, Luo T, Ayala R, Salgar S, et al.
Breast Cancer Res
. 2020 Aug;
22(1):89.
PMID: 32795346
Background: Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2- breast cancer. However, acquired resistance to these therapies frequently leads to disease...
9.
McDermott M, Sharko A, Munie J, Kassler S, Melendez T, Lim C, et al.
Cells
. 2020 Mar;
9(3).
PMID: 32155786
CDK7, a transcriptional cyclin-dependent kinase, is emerging as a novel cancer target. Triple-negative breast cancers (TNBC) but not estrogen receptor-positive (ER+) breast cancers have been reported to be uniquely sensitive...
10.
McDermott M, Conlon N, Browne B, Szabo A, Synnott N, OBrien N, et al.
Cancers (Basel)
. 2019 Feb;
11(2).
PMID: 30743996
Prolonged treatment of HER2 positive breast cancer cells with tyrosine kinase inhibitors (TKIs) leads to the emergence of acquired resistance. However, the effects of continuous TKI exposure on cell fate,...